Perhaps no industry is as prone to eye-popping pops and drops as biotechnology. The basket can trade wildly on the latest whims and whispers surrounding clinical trials and timelines. Yet, despite the risk, some of the planet’s savviest investors are buying shares in these stocks. For example, Carl Icahn bought Allergan plc (NYSE: AGN) and George Soros bought the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB). Those are just two of a slate of investments that billionaires have been making in the industry recently.